Experts Outline Future of Radiopharmaceutical Therapy
Prof. Wolfgang Wadsak presented new radiopharmaceutical trends during the October 2026 EANM conference in Vienna.
Updated on Oct. 21, 2026 in Nuclear
Live Poll
Should medical systems prioritize expanding existing treatment availability over developing experimental new cancer therapies?
At the October 2026 EANM conference, Prof. Wolfgang Wadsak addressed the evolving landscape of radiopharmaceutical development and cancer treatment. He highlighted current advancements in PSMA-targeted therapies alongside the logistical challenges facing the field.
Why it matters
The development of new targets for breast, ovarian, and lung cancers is essential to broadening the scope of personalized oncology. Expanding these treatment options relies on overcoming significant hurdles in production capacity and rising costs.
Current research focuses on PSMA-targeted therapy and the utilization of new molecular targets such as ACP3. These advancements aim to expand the range of available radionuclides for personalized medicine.
The players
Wolfgang Wadsak
He is the chair of the EANM Guidelines and Publications Council and performs radiopharmaceutical preparation at the MINUTE medical clinic in Vienna.
The details
Prof. Wolfgang Wadsak emphasized that the industry must balance rising clinical potential with the reality of an infrastructure heavily dependent on aging research reactors. Integrating therapies like PSMA radioligand treatment earlier in the course of prostate cancer remains a primary objective for oncology experts.
Timeline
October 2026: The EANM conference took place in Vienna.
The Big Picture
This discourse follows the standard set by the European Association of Nuclear Medicine (EANM) Guidelines regarding the integration of new molecular targets. It shifts the discipline toward earlier intervention models in cancer therapy.
Improved radiopharmaceutical protocols could lead to more precise, personalized cancer treatments for patients with breast, lung, or prostate cancers. These clinical developments aim to enhance efficacy and extend the availability of targeted therapies over time.
The takeaway
The transition toward earlier PSMA-targeted therapy reflects a broader push for precision in oncology. Patients should discuss emerging radioligand options with their specialists to understand how these therapies might fit into their broader treatment plans.
Further reading
Learn more about the latest innovations in this field in the Nuclear section.
Source note: This article includes information reported by AuntMinnieEurope.
Live Poll
Should medical systems prioritize expanding existing treatment availability over developing experimental new cancer therapies?
